Redox Signaling Advances in Cancer Research Series

Advances in Cancer Research, Volume 162 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors

1. Cellular cysteine sources and availability in cancer
Ed Schmidt
2. PTP1B
Lalima Katyayani K. Madan
3. Mitochondrial metallopeptidase OMA1 in cancer
Oleh Khalimonchuk
4. Redox Regulation of VDAK
Eduardo Nestor Maldonado
5. Role of thiols or antioxidants in modulating immune response
Shikhar Mehrotra
6. Redox regulation in melanoma metastasis and targeted therapy resistance
Danyelle Townsend and Jie Zhang
7. chapter to be determined
Kenneth D. Tew
8. title yet to be determined
Hozumi Motohashi
9. title yet to be determined
Mark Hampton
10. title yet to be determined
Colin Miller
11. GRP78 as novel molecular targets through ER stress modulation in lung cancer
Zhi-wei Ye

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at John